FI  GenHenn Capital

https://www.genhenncapital.com/





     Office Locations:

P.O. Box 692
Cranbury, NJ 08512

 

Stages:

  • Early
  • Seed


 

Industries:

  • Information Technology
  • Life Sciences & Healthcare
  • Software & Internet

  •  

    Description:

    Founded in 2022, GenHenn Capital is a single-family office that specializes in private equity and venture capital investments. GenHenn Capital is a mid to long term investor that seeks to elevate companies that have unique technology with an emphasis on the life sciences, healthcare, infrastructure, biotechnology, and information technology sectors. The firm's principals include Michael J. Hennessy, Jr, currently serves as Chief Executive Officer (CEO) and President for MJH Life Sciences, the largest privately held, independent, full-service medical media company;



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Michael J. Hennessy Principal
    William Hagman COO

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      08/21/2024


      PreciseDx


      NY


      $20,700,000


      Series B


      08/12/2024


      Prana Thoracic


      TX


      $3,000,000


      Series A Extension


     

    Portfolio companies include:


      Diligent Pharma
        web link


      Mend


      Prana Thoracic
        web link


      PreciseDx
        web link


     

    Recent News: